# Phase II Study of Pazopanib and Topotecan in Cervical Cancer

> **NCT02348398** · PHASE2 · WITHDRAWN · sponsor: **M.D. Anderson Cancer Center**

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** Pazopanib
- **DRUG:** Topotecan
- **BEHAVIORAL:** Phone Call

## Key facts

- **NCT ID:** NCT02348398
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-08
- **Primary completion:** 2019-08
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02348398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02348398, "Phase II Study of Pazopanib and Topotecan in Cervical Cancer". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT02348398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*